Cellectar Raises $2.7 Million for Cancer Drug Development
Posted: February 22, 2010 - 6:00 PM
A Madison company that is testing a radioactive drug with potential to identify and treat tumors has raised $2.7 million of funding, according to a filing with the Securities and Exchange Commission.
Cellectar Inc. currently has its lead compound, called CLR1404, in Phase 1 clinical trials for cancer treatment.
Click Here to read the full article
Medallion Members
- Platinum
- Silver
- Bronze
